Boston Scientific (NYSE:BSX) said it closed the $275 million acquisition of C.R. Bard‘s (NYSE:BCR) electrophysiology business it announced last June.
The Lowell, Mass.-based EP unit rang up about $111 million in sales of its catheters and accessories last year.
Pete Sommerness, general manager of electrophysiology for Natick, Mass.-based Boston Scientific, told MassDevice.com that the Bard operation is "highly complementary" to the legacy EP business he oversees.
"The product lines mesh very well together," Sommerness said. "Their team, particularly in some geographies that are growth opportunities for us, is very strong. In Europe and parts of Asia, they have invested in people and training and skills that are very timely for us as we look to expand our position."
Boston Scientific affirmed that it expects the deal to help accelerate launches of key EP technologies including its IntellaTip MiFi XP ablation catheter and Rhythmia mapping system.
The addition of the 180-employee Bard EP business should be neutral this year and add 1¢ to its adjusted EPS in 2014, the company said.